Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $1,000,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $125.00, for a total value of $1,000,000.00. Following the completion of the transaction, the insider directly owned 204,000 shares in the company, valued at approximately $25,500,000. The trade was a 3.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total value of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $785,760.00.

Billiontoone Stock Down 2.8%

NASDAQ:BLLN traded down $3.52 during mid-day trading on Monday, reaching $123.25. The stock had a trading volume of 596,578 shares, compared to its average volume of 490,947. The business’s 50 day moving average is $100.50 and its 200 day moving average is $88.83. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $138.70. The stock has a market cap of $5.67 billion and a P/E ratio of 224.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. Billiontoone’s revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) EPS. As a group, sell-side analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BLLN has been the subject of several analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. BTIG Research cut their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Guggenheim assumed coverage on Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. Rossby Financial LCC bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone during the 4th quarter worth $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone during the 4th quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone in the 4th quarter worth $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.